Cephalon's Oravescent Fentanyl Hits Primary Endpoint In Phase III May 6, 2005 By Aaron Lorenzo In reporting positive results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track to submit a new drug application to the FDA next quarter. (BioWorld Today)Read More
RSS